VAXCYTE, INC. Net Income
VAXCYTE, INC. (PCVX) reported Net Income of -$284.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- VAXCYTE, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$284.30M.
- VAXCYTE, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$320.62M.
- VAXCYTE, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $519.35M, a 59.12% increase year-over-year.
- VAXCYTE, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$212.83M.
- VAXCYTE, INC. net income (loss) attributable to parent for fiscal 2020 was -$89.22M.
- VAXCYTE, INC. net income (loss) attributable to parent for fiscal 2019 was -$50.27M.
- VAXCYTE, INC. net income (loss) attributable to parent for fiscal 2018 was -$29.48M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$284.30M 10-Q · filed 2026-08-05 | -$604.92M 10-Q · filed 2026-08-05 | -$85.57M derived: sum of 3 quarters · filed 2026-08-05 | -$298.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$320.62M 10-Q · filed 2026-08-05 | $198.73M derived: sum of 2 quarters · filed 2026-08-05 | -$14.10M derived: sum of 3 quarters · filed 2026-08-05 | -$180.67M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $519.35M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $306.52M derived: sum of 2 quarters · filed 2026-04-23 | $139.95M derived: sum of 3 quarters · filed 2026-08-05 | -$766.63K DEF 14A · filed 2026-04-23 | -$766.63M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$212.83M 10-Q · filed 2025-11-04 | -$379.40M derived: sum of 2 quarters · filed 2026-08-05 | -$520.12M 10-Q · filed 2025-11-04 | -$193.74M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$166.57M 10-Q · filed 2026-08-05 | -$307.29M 10-Q · filed 2026-08-05 | $19.09M derived: sum of 3 quarters · filed 2026-08-05 | -$84.03M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$140.72M 10-Q · filed 2026-08-05 | $185.67M derived: sum of 2 quarters · filed 2026-08-05 | $82.54M derived: sum of 3 quarters · filed 2026-08-05 | -$46.16M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2024-12-31 | $326.38M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $223.26M derived: sum of 2 quarters · filed 2026-04-23 | $94.56M derived: sum of 3 quarters · filed 2026-04-23 | -$463.93K DEF 14A · filed 2026-04-23 | -$463.93M 10-K · filed 2025-02-25 |
| 2024-09-30 | -$103.12M 10-Q · filed 2025-11-04 | -$231.83M derived: sum of 2 quarters · filed 2025-11-04 | -$326.85M 10-Q · filed 2025-11-04 | -$105.78M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2024-06-30 | -$128.70M 10-Q · filed 2025-11-04 | -$223.72M 10-Q · filed 2025-08-06 | -$2.66M derived: sum of 3 quarters · filed 2026-04-23 | -$95.32M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2024-03-31 | -$95.02M 10-Q · filed 2025-11-04 | $126.04M derived: sum of 2 quarters · filed 2026-04-23 | $33.38M derived: sum of 3 quarters · filed 2026-04-23 | -$34.96M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-12-31 | $221.06M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $128.40M derived: sum of 2 quarters · filed 2026-04-23 | $60.06M derived: sum of 3 quarters · filed 2026-04-23 | -$402.27K DEF 14A · filed 2026-04-23 | -$402.27M 10-K · filed 2024-02-27 |
| 2023-09-30 | -$92.66M 10-Q · filed 2024-11-05 | -$161.00M derived: sum of 2 quarters · filed 2024-11-05 | -$221.47M 10-Q · filed 2024-11-05 | -$76.25M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-06-30 | -$68.34M 10-Q · filed 2024-11-05 | -$128.80M 10-Q · filed 2024-08-06 | $16.41M derived: sum of 3 quarters · filed 2026-04-23 | -$41.51M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2023-03-31 | -$60.46M 10-Q · filed 2024-11-05 | $84.75M derived: sum of 2 quarters · filed 2026-04-23 | $26.83M derived: sum of 3 quarters · filed 2026-04-23 | -$21.70M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2022-12-31 | $145.21M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $87.29M derived: sum of 2 quarters · filed 2026-04-23 | $38.76M derived: sum of 3 quarters · filed 2026-04-23 | -$223.49K DEF 14A · filed 2026-04-23 | -$223.49M 10-K · filed 2023-02-27 |
| 2022-09-30 | -$57.92M 10-Q · filed 2023-11-06 | -$106.45M derived: sum of 2 quarters · filed 2023-11-06 | -$145.44M 10-Q · filed 2023-11-06 | -$74.02M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2022-06-30 | -$48.53M 10-Q · filed 2023-11-06 | -$87.52M 10-Q · filed 2023-08-08 | -$16.10M derived: sum of 3 quarters · filed 2026-04-23 | -$42.72M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2022-03-31 | -$38.99M 10-Q · filed 2023-11-06 | $32.43M derived: sum of 2 quarters · filed 2026-04-23 | $5.81M derived: sum of 3 quarters · filed 2026-04-23 | -$17.87M derived: sum of 4 quarters · filed 2026-04-23 | |
| 2021-12-31 | $71.41M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-23 | $44.80M derived: sum of 2 quarters · filed 2026-04-23 | $21.12M derived: sum of 3 quarters · filed 2026-04-23 | -$100.08K DEF 14A · filed 2026-04-23 | -$100.08M 10-K · filed 2022-02-28 |
| 2021-09-30 | -$26.61M 10-Q · filed 2022-11-07 | -$50.29M derived: sum of 2 quarters · filed 2022-11-07 | -$71.51M 10-Q · filed 2022-11-07 | -$92.25M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | -$23.68M 10-Q · filed 2022-11-07 | -$44.90M 10-Q · filed 2022-08-08 | -$65.64M derived: sum of 3 quarters · filed 2022-11-07 | -$86.65M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-03-31 | -$21.22M 10-Q · filed 2022-11-07 | -$41.96M derived: sum of 2 quarters · filed 2022-11-07 | -$62.98M derived: sum of 3 quarters · filed 2022-11-07 | -$83.30M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2020-12-31 | -$20.74M 10-K · filed 2021-03-29 | -$41.76M derived: sum of 2 quarters · filed 2021-11-10 | -$62.08M derived: sum of 3 quarters · filed 2021-11-10 | -$89.22M 10-K · filed 2023-02-27 | |
| 2020-09-30 | -$21.02M 10-Q · filed 2021-11-10 | -$41.34M derived: sum of 2 quarters · filed 2021-11-10 | -$68.48M 10-Q · filed 2021-11-10 | -$83.10M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$20.32M 10-Q · filed 2021-11-10 | -$47.46M 10-Q · filed 2021-08-11 | -$62.08M derived: sum of 3 quarters · filed 2021-11-10 | -$73.40M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-03-31 | -$27.14M 10-Q · filed 2021-11-10 | -$41.76M derived: sum of 2 quarters · filed 2021-11-10 | -$53.08M derived: sum of 3 quarters · filed 2021-11-10 | -$63.74M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2019-12-31 | -$14.62M 10-K · filed 2021-03-29 | -$25.94M derived: sum of 2 quarters · filed 2021-03-29 | -$36.60M derived: sum of 3 quarters · filed 2021-03-29 | -$50.27M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$11.32M 10-K · filed 2021-03-29 | -$21.98M derived: sum of 2 quarters · filed 2021-03-29 | -$35.65M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$10.66M 10-K · filed 2021-03-29 | -$24.34M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | -$13.67M 10-K · filed 2021-03-29 | ||||
| 2018-12-31 | -$29.48M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |